Details
Description
In this report, we examined uptake of brodalumab in the Sentinel Distributed Database (SDD). This is the first report of an ongoing plan to monitor uptake of brodalumab until sufficient follow-up accrues among treated patients to conduct an inferential analysis examining rates of serious infection, acute myocardial infarction/stroke, and inpatient neutropenia in plaque psoriasis patients initiating brodalumab compared to plaque psoriasis patients initiating non-brodalumab biologics.
The study period includes data from February 15, 2017 to February 29, 2020. We distributed this request to seven Sentinel Data Partners on January 7, 2021.